Hydroxychloroquinesulfaat Accord

Hydroxychloroquine, the active ingredient in Hydroxychloroquinesulfaat Accord, is an antimalarial presented as an oral dosage form for oral use. It is employed in the treatment and management of malaria, rheumatoid arthritis, and systemic lupus erythematosus in adult patients.

GNH USA supplies Hydroxychloroquinesulfaat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for import and distribution.

Hydroxychloroquine is a disease‑modifying antirheumatic drug that interferes with malaria parasite replication and modulates immune activity.

- Malaria: reduces parasite load and prevents disease progression. - Rheumatoid arthritis: alleviates joint inflammation and slows structural damage. - Systemic lupus erythematosus: decreases disease activity and flares.

Hydroxychloroquine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial pain. - Skin rash: mild erythema or itching. - Visual disturbances: blurred vision or difficulty focusing.

Serious or Rare Side Effects: - Retinopathy: irreversible retinal damage with prolonged use. - Cardiotoxicity: arrhythmias or conduction abnormalities. - Severe hypoglycemia: marked blood glucose reduction, especially with antidiabetic drugs. - Hemolytic anemia: especially in patients with G6PD deficiency. - Neuropsychiatric effects: agitation, depression, or psychosis.

Before initiating therapy with hydroxychloroquine, several safety considerations should be reviewed. - Pregnancy: safety category unknown; use only if potential benefit justifies risk. - Breastfeeding: unknown; weigh benefits against possible infant exposure. - G6PD deficiency: risk of hemolysis; assess enzyme status prior to treatment. - Retinal monitoring: baseline eye exam and annual follow‑up recommended. - Drug interactions: review concomitant medications for QT prolongation risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Hydroxychloroquine interacts with several medicines that may alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Azithromycin or other QT‑prolonging agents: may cause serious cardiac arrhythmias. - Digoxin: increased serum levels leading to toxicity. - Cyclosporine: heightened risk of retinal toxicity.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs (insulin, sulfonylureas): may cause severe hypoglycemia. - Antiepileptics (phenytoin, carbamazepine): may reduce hydroxychloroquine concentrations. - Rifampicin: may lower drug exposure, reducing effectiveness. - Warfarin: potential alteration of INR, requiring closer monitoring.